Investigator-assessed PFS and OS. (A) PFS in the overall population. (B) PFS in patients with del(17p)/TP53^mut. (C) PFS when assessing only for progression or death events occurring on active treatment. (D) PFS when adjusted for COVID-19 deaths. (E) OS.